Long-term survivors of glioblastoma: clinical features and IDH1/2 mutation analysis
YU Lei
LI De-pei
LU Jie
QI Song-tao
Abstract：Objective To describe the clinical characteristics of the GBM long-term survivors (LTS) with IDH1/2 mutations and investigate its association with overall survival (OS).Methods Records of 92 newly diagnosed primary adult GBM patients who survived at least 36 months after operation were retrospectively reviewed.Descriptive statistics of clinical characteristics, treatments received, and tumor biomarkers were reported.Estimates for progression-free survival (PFS) and overall survival (OS) were provided.Results In the 368 newly diagnosed adult GBM patients treated at a single institution from January 2009 to December 2010, 92 (25%) LTS GBM patients were identified, with a median age of 45.6±2.8 years and a median preoperative Karnofsky Performance Score (KPS) of 80±10.The surgical principle was resection of the parenchyma beyond the area of signal abnormalities on T2/FLAIR-weighted MRI (known to be invaded by tumor cells) until eloquent structures were detected for non-eloquent tumors and the parenchyma of contrast enhanced T1WI for eloquent or deep-sited tumors.The OS was 3-8 years (median OS 5 years).PFS rates at 12, 36, and 60 months were 89.5%, 56.3%, and 48.2%, respectively.Among the 84 GBM LTS with enough tumor samples for genetic testing, 16 (16/84, 17.4%) had IDH1/2 mutations.No significant difference in median PFS or OS was found between IDH1/2 mutated and wild-type patients.Conclusion Aggressive surgery is the basic guarantee for LTS in GBM patients.IDH1/2 status does not explain most of the long-term survivorship.
Keywords：glioblastoma multiforme (GBM)isocitrate dehydrogenase 1/2(IDH1/2)long-term survivors (LTS)progression-free survival (PFS)overall survival (OS)
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 2129-2134 )